Jason M. Broderick

Arvind N. Dasari, MD, MS, reviews a year in neuroendocrine tumors marked by expanding radioligand options, improved classification, and disappointing combination therapies.

Older age, kidney disease, and prior irradiation were linked to elevated myeloid neoplasm risk after lutetium Lu 177 dotatate in a real-world NET analysis.

Claire K. Mulvey, MD, explains how patient-reported outcomes and QOL assessments reveal NEN symptom burden and help guide treatment.

Liver transplant led to durable survival in unresectable NET liver metastases; tumor burden predicted outcomes, and recurrence was common but treatable.

Erica S. Alexander, MD, highlights endovascular approaches to venous occlusion, including stenting and thrombolysis, for select patients with NETs.

In a phase 1 trial, a single intratumoral injection of oncolytic virus SVV-001 with ipilimumab and nivolumab was safe in high-grade neuroendocrine cancers.

Zocilurtatug pelitecan, a DLL3-targeted ADC, showed meaningful responses and managea-ble safety in previously treated epNEC, regardless of DLL3 expression.

In DAREON-7, first-line obrixtamig plus chemo yielded responses across DLL3 expression levels in epNEC, with the most durable in DLL3-high tumors.

In the CABINET trial, cabozantinib extended PFS vs placebo in advanced NETs regardless of hormone functional status, with similar safety across subgroups.

Jennifer R. Eads, MD, discussed radioligand therapy in younger and older patients with NETs, highlighting safety data and gaps in clinical evidence.

PRRT retreatment achieved high disease control in NETs, and longer benefit from first PRRT was tied to longer progression-free survival after retreatment.

The investigational alpha emitter 212Pb-VMT-α-NET yielded encouraging response rates in PRRT-naive SSTR2+ NETs.

Erik S. Mittra, MD, PhD, highlighted how new PRRT trials may reshape neuroendocrine tumor care, from retreatment and dosimetry to alpha-emitting therapies.

The FDA has granted accelerated approval to amivantamab and hyaluronidase for advanced HNSCC based on the OrigAMI-4 trial.

ESMO 2026 Presidential Symposium III: ADC and immunotherapy highlights from the the ARTEMIS-011, TroFuse-005, KEYNOTE-C93, and MOIO trials.

ESMO 2026 Presidential Symposium II recap: survival benefits reported across phase 3 Krascendo 1, SAFFRON, CLARITY-Gastric01, and HARMONi-GI1 trials.

Preview the late-breaking studies at ESMO Congress 2026, from KRAS inhibitors and ADCs to bispecifics and perioperative immunotherapy across tumor types.

Andrew T. Kuykendall, MD, explains the significance of the FDA approval of rusfertide for polycythemia vera.

The FDA will use the extension to review additional data supporting the NDA for zanzalintinib plus atezolizumab for metastatic colorectal cancer.

Geoffrey Y. Ku, MD, highlights emerging therapies in the treatment paradigm for patients with gastric and gastroesophageal junction cancers.

The approval is primarily supported by the phase 3 VERIFY study.

Shubham Pant, MD, MBBS, explains the significance of the FDA approval of daraxonrasib for mPDAC.

Varsetatug masetecan is a first-in-class ADC that pairs a monoclonal antibody against EpCAM with a topoisomerase 1 inhibitor payload.

The approval of daraxonrasib in pancreatic cancer is supported by results from the phase 3 RASolute 302 trial.

The sBLA for dostarlimab in dMMR/MSI-H rectal cancer is based on the AZUR-1 trial.

"Although I am disappointed that the PFS improvement was not statistically significant, I look forward to continuing to follow these results," Robert Coleman, MD.

The sBLA for subcutaneous amivantamab is supported by results from the phase 1b/2 OrigAMI-4 study.

Sonesitatug vedotin boosted overall survival vs chemotherapy in second-line and later CLDN18.2-positive gastric/GEJ cancers.

Early phase 2 data show IMNN-001 added to chemo plus bevacizumab reduces residual ovarian cancer, boosts ctDNA clearance, and remains well tolerated.

The NDA for daraxonrasib in PDAC is supported by results from the phase 3 RASolute 302 trial.